Kiniksa Pharmaceuticals International, plc (KNSA) Cash Flow Statement
Kiniksa Pharmaceuticals International, plc (KNSA) generated $185.0M of operating cash flow over the twelve months to 2026-06-30, spent $2.1M on capital expenditure and had free cash flow of $182.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KNSAKiniksa Pharmaceuticals International, plcFollow KNSA — free
—
Price chart with a free account
- Market cap
- 6.0B
- P/E TTM
- 78.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 26 Oct, in 2 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -126.3 | 5.8 | 13.3 | 25.7 | 138.0 | 185.0 | |
| Capital expenditure | 0.4 | 0.1 | 0.1 | 0.3 | 1.6 | -2.1 | |
| Free cash flow | -126.7 | 5.7 | 13.2 | 25.4 | 136.4 | 182.8 | |
| Dividends paid | 0.0 | 0.0 | 0.0 | — | 0.0 | — | |
| Stock-based compensation | 25.2 | 25.1 | 27.1 | 30.7 | 37.0 | — |
USD millions · SEC XBRL
Kiniksa Pharmaceuticals International, plc — questions
- What is Kiniksa Pharmaceuticals International, plc's operating cash flow?
- $185.0M over the twelve months to 2026-06-30.
- How much does Kiniksa Pharmaceuticals International, plc spend on capital expenditure?
- $2.1M over the twelve months to 2026-06-30.
- What is Kiniksa Pharmaceuticals International, plc's free cash flow?
- $182.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Kiniksa Pharmaceuticals International, plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.